ClinicalTrials.gg
RecruitingNCT06431477Updated May 28, 2024

Efficacy and Safety of Telmisartan Compared With Losartan

A Phase 4 interventional study of telmisartan and Losartan in Diabetic Nephropathies and Hypertension, sponsored by Chong Kun Dang Pharmaceutical. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-28.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Apr 2023, registered May 2024).
  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Diabetic Nephropathies with a site in Korea, Republic of — 4 open to participants now, 5 under way, 1 of them phase 3. Diabetic Nephropathies · Korea, Republic of.

Planned enrollment
21st of 24
98 · median 233
Started
2023
with 1 other
Phase 4
5 of 25
1 open now
Registered
22nd of 25
by date

Among the 25 studies in Diabetic Nephropathies with a site in Korea, Republic of, this one is the 21st largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 4, and was the 22nd registered.

Diabetic Nephropathies

543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

4 of the 25 studies in Diabetic Nephropathies with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Diabetic Nephropathies with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A study to evaluate the efficacy and safety of telmisartan compared with losartan in patients with diabetic nephropathy and hypertension

Read the detailed description

A Multi-center, Randomized, Open-label, Active comparator-controlled, Phase 4 Clinical Trial To Evaluate the Efficacy and Safety of Telmisartan Compared with Losartan in Patients with Diabetic Nephropathy and Hypertension

03

Conditions studied

  • Diabetic Nephropathies
  • Hypertension
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male of Female subjects aged ≥19 or \<75
  • Type II Diabetes Mellitus subjects who have been taken medicine
  • Subjects who have voluntarily decided to participate in this clinical trial and Signed ICF

Exclusion criteria

Exclusion Criteria:

  • Subjects with Type I Diabetes Mellitus
  • Subjects with Primary hyper-aldosteronism
  • Subjects with a history of drug or alcohol abuse or suspected patient within 1 year as of the time of screening
  • Pregnant women, lactating women, or subjects who do not agree to use appropriate during the clinical trial period
  • Subjects who received other clinical trial drugs within 28 days of screening visit
  • Subjects who are unable to participate in this clinical trial at the discretion of the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    Telmisartan tablet

    Drug: telmisartan

  • Active comparator
    Losartan tablet

    Drug: Losartan

Interventions

06

What researchers measure

Primary outcomes

  1. Change rate from baseline in Spot-UACR(Albumin/Creatinine Ratio)

    Time frame: 24 weeks after drug administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Oct 2025, 30 months after the start.

Of 21 phase 4 interventional studies under Diabetic Nephropathies, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's planned 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
May 28, 2024
StartActual
Apr 19, 2023
Primary completionEst.
Oct 31, 2025
CompletionEst.
Oct 31, 2025
Last update
May 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06431477
Responsible party
Sponsor
First posted
May 28, 2024
Start date
Apr 19, 2023
Primary completion
Oct 31, 2025 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
May 28, 2024

Study contacts

BeomSeok Kim, M.D, Ph.D
Contact
DOCBSK@yuhs.ac
+82-2-2228-5331
BeomSeok Kim, M.D, Ph.D
principal investigator · Severance Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion